BRPI0510963A - derivados pirimidina para o tratamento do crescimento anormal de células - Google Patents

derivados pirimidina para o tratamento do crescimento anormal de células

Info

Publication number
BRPI0510963A
BRPI0510963A BRPI0510963-9A BRPI0510963A BRPI0510963A BR PI0510963 A BRPI0510963 A BR PI0510963A BR PI0510963 A BRPI0510963 A BR PI0510963A BR PI0510963 A BRPI0510963 A BR PI0510963A
Authority
BR
Brazil
Prior art keywords
cell growth
abnormal cell
treatment
pyrimidine derivatives
mammals
Prior art date
Application number
BRPI0510963-9A
Other languages
English (en)
Inventor
John Charles Kath
Michael Joseph Luzzio
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0510963A publication Critical patent/BRPI0510963A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

DERIVADOS PIRIMIDINA PARA O TRATAMENTO DO CRESCIMENTO ANORMAL DE CéLULAS A presente invenção está relacionada a um composto de fórmula (1) onde R¬ 1¬-R¬ 4¬ e Ar são como definidos aqui. Tais derivados pirimidina são úteis no tratamento do crescimento anormal de células, tais como o câncer em mamíferos. Essa invenção também está relacionada a um método de utilização de tais compostos no tratamento do crescimento anormal de células em mamíferos, especialmente humanos, e a composições farmacêuticas contendo tais compostos.
BRPI0510963-9A 2004-05-14 2005-05-02 derivados pirimidina para o tratamento do crescimento anormal de células BRPI0510963A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57120904P 2004-05-14 2004-05-14
PCT/IB2005/001291 WO2005111016A1 (en) 2004-05-14 2005-05-02 Pyrimidine derivatives for the treatment of abnormal cell growth

Publications (1)

Publication Number Publication Date
BRPI0510963A true BRPI0510963A (pt) 2007-11-20

Family

ID=34967760

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510963-9A BRPI0510963A (pt) 2004-05-14 2005-05-02 derivados pirimidina para o tratamento do crescimento anormal de células

Country Status (9)

Country Link
US (1) US7235562B2 (pt)
EP (1) EP1758887A1 (pt)
JP (1) JP2007537238A (pt)
AR (1) AR049424A1 (pt)
BR (1) BRPI0510963A (pt)
CA (1) CA2564199A1 (pt)
MX (1) MXPA06013165A (pt)
TW (1) TW200612949A (pt)
WO (1) WO2005111016A1 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
EA013248B1 (ru) * 2002-12-20 2010-04-30 Пфайзер Продактс Инк. Производные пиримидина для лечения патологического роста клеток
US20060205945A1 (en) * 2004-05-14 2006-09-14 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7754714B2 (en) * 2004-05-18 2010-07-13 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
WO2007063384A2 (en) * 2005-12-01 2007-06-07 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US8153791B2 (en) 2005-12-21 2012-04-10 Janssen Pharmaceutica N.V. Substituted pyrimidinyl oxime kinase inhibitors
RS20080272A (sr) * 2005-12-21 2009-07-15 Pfizer Products Inc., Derivati pirimidina za tretman neprirodnog rasta ćelija
US20070203224A1 (en) * 2006-01-09 2007-08-30 University Of Southern California Small-molecules for treating cancer and abnormal cell proliferation disorders
WO2007109783A2 (en) * 2006-03-23 2007-09-27 Janssen Pharmaceutica, N.V. Substituted pyrimidine kinase inhibitors
ES2555803T3 (es) 2006-10-23 2016-01-08 Cephalon, Inc. Fusión de derivados bicíclicos 2,4-diaminopirimidina como utilizar inhibidores ALK y c-Met
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
AP2009005010A0 (en) 2007-04-18 2009-10-31 Pfizer Prod Inc Sulfonyl amide derivatives for the treatment of abnormal cell growth
KR101294731B1 (ko) * 2007-06-04 2013-08-16 삼성디스플레이 주식회사 어레이 기판, 이를 갖는 표시패널 및 이의 제조방법
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
WO2009011861A1 (en) * 2007-07-16 2009-01-22 Poniard Pharmaceuticals, Inc. Oral formulations for picoplatin
EP2249644A4 (en) * 2008-02-08 2012-05-30 Poniard Pharmaceuticals Inc PICOPLATIN AND AMRUBICIN FOR THE TREATMENT OF LUNG CANCER
US8592432B2 (en) * 2008-04-07 2013-11-26 Bei Chen Compounds and compositions as protein kinase inhibitors
BR112012029647A2 (pt) 2010-05-21 2016-08-02 Chemilia Ab novos derivados de pirimidinas
US8354420B2 (en) 2010-06-04 2013-01-15 Genentech, Inc. Aminopyrimidine derivatives as LRRK2 inhibitors
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
SI2638031T1 (en) 2010-11-10 2018-02-28 Genentech, Inc. Pyrazole aminopyrimidine derivatives as LRRK2 modulators
JP5886411B2 (ja) 2011-03-24 2016-03-16 ノビガ・リサーチ・エービーＮｏｖｉｇａ Ｒｅｓｅａｒｃｈ ＡＢ 新規のピリミジン誘導体
JP6118808B2 (ja) * 2011-10-31 2017-04-19 ザ メソジスト ホスピタル リサーチ インスティテュート ヒトグリオームを治療するためのｍａｏ標的化／探索部分を含む化合物
CN103958498B (zh) * 2011-11-29 2016-09-07 霍夫曼-拉罗奇有限公司 作为lrrk2调节剂的氨基嘧啶衍生物
WO2015158310A1 (zh) * 2014-04-18 2015-10-22 山东轩竹医药科技有限公司 一种酪氨酸激酶抑制剂及其用途
US10428030B2 (en) 2015-10-30 2019-10-01 Trillium Therapeutics Heterocycle derivatives and their use for the treatment of CNS disorders
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
EP3679028A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Dihydroquinolinones
AU2019414550B2 (en) * 2018-12-27 2022-09-22 Hinova Pharmaceuticals Inc. FAK inhibitor and drug combination thereof
CN115515588A (zh) 2020-02-14 2022-12-23 萨克生物研究学院 大环ulk1/2抑制剂
AU2021218740A1 (en) * 2020-02-14 2022-09-22 Salk Institute For Biological Studies Mono and combination therapies with ULK1/2 inhibitors
WO2022199561A1 (zh) * 2021-03-23 2022-09-29 杭州阿诺生物医药科技有限公司 Hpk1激酶抑制剂化合物
WO2022214009A1 (zh) * 2021-04-08 2022-10-13 杭州阿诺生物医药科技有限公司 一种高活性的hpk1激酶抑制剂

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US162802A (en) * 1875-05-04 Improvement in light-house lanterns
US171359A (en) * 1875-12-21 Improvement in bearings for journals
US181A (en) * 1837-04-25 Bodkin fob inserting corset or other grooved rings into cloth or canvas
US4507146A (en) * 1982-12-28 1985-03-26 Ciba-Geigy Corporation 2,4-Diamino-6-halo-5-trifluoromethylpyrimidines having herbicidal activity
US4864021A (en) * 1984-10-30 1989-09-05 Otsuka Pharmaceutical Co., Ltd. 5-fluorouracil derivatives
US4983608A (en) * 1989-09-05 1991-01-08 Hoechst-Roussell Pharmaceuticals, Inc. N-substituted-4-pyrimidinamines and pyrimidinediamines
DE4029650A1 (de) 1990-09-19 1992-03-26 Hoechst Ag 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide
AU2954992A (en) 1991-11-13 1993-06-15 Mta Kozponti Kemiai Kutato Intezete Process for preparing n-(arylsulphonyl)-carbamide acid derivates and intermediates useful for carrying out this process
DE4137291A1 (de) 1991-11-13 1993-05-19 Bayer Ag Verfahren zur kontinuierlichen umsetzung von halogenpyrimidinen mit aminen
FR2686339B1 (fr) 1992-01-22 1994-03-11 Adir Cie Nouveaux amides et sulfonamides naphtaleniques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
ES2149815T3 (es) 1992-05-22 2000-11-16 Du Pont Imidazolinonas fungicidas.
EP0856001B1 (en) * 1995-10-02 2002-08-28 F. Hoffmann-La Roche Ag Pyrimidine derivatives as 5ht2c receptor antagonists
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
TW440563B (en) * 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
NZ333727A (en) 1996-08-06 2000-09-29 Pfizer Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic arylsulfonylamino hydroxamic acid derivatives
PL332187A1 (en) 1996-09-04 1999-08-30 Pfizer Substitution derivatives of indazole and their application as inhibitors of phosphodiesterase (pde) of iv type and tumor necrosis factor (tnf)
JP4495257B2 (ja) 1997-02-19 2010-06-30 バーレツクス ラボラトリーズ インコーポレーテツド Ｎｏｓ抑制剤としてのｎ−複素環誘導体
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
JP2002503662A (ja) 1998-02-17 2002-02-05 テュラリク インコーポレイテッド 抗ウイルス性ピリミジン誘導体
DE69933680T2 (de) 1998-08-29 2007-08-23 Astrazeneca Ab Pyrimidine verbindungen
AU6159499A (en) 1998-09-29 2000-04-17 Wyeth Holdings Corporation Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
GB9924862D0 (en) * 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
HUP0301117A3 (en) 2000-02-17 2004-01-28 Amgen Inc Thousand Oaks Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
IL151249A0 (en) 2000-03-13 2003-04-10 American Cyanamid Co Use of cyanoquinolines for treating or inhibiting colonic polyps
US6525051B2 (en) 2000-03-27 2003-02-25 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
AU2001269291A1 (en) 2000-07-07 2002-02-05 Cancer Research Technology Limited Therapeutic acridone and acridine compounds
AU2001276521B2 (en) 2000-08-09 2006-05-25 Astrazeneca Ab Cinnoline compounds
CA2416525A1 (en) 2000-08-09 2002-02-14 Astrazeneca Ab Indole, azaindole and indazole derivatives having vegf inhibiting activity
WO2002016348A1 (en) 2000-08-09 2002-02-28 Astrazeneca Ab Antiangiogenic bicyclic derivatives
US7115615B2 (en) 2000-08-21 2006-10-03 Astrazeneca Quinazoline derivatives
JO2654B1 (en) 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
ES2556946T3 (es) 2000-12-21 2016-01-21 Novartis Ag Pirimidinaminas como moduladores de la angiogénesis
AU2002312933B2 (en) 2001-05-29 2007-12-06 Schering Ag CDK inhibiting pyrimidines, production thereof and their use as medicaments
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
WO2002102313A2 (en) * 2001-06-19 2002-12-27 Bristol-Myers Squibb Company Pyrimidine inhibitors of phosphodiesterase (pde) 7
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US6927293B2 (en) * 2001-08-30 2005-08-09 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
DK1438053T3 (da) * 2001-10-17 2008-12-08 Boehringer Ingelheim Pharma Pyrimidinderivater, lægemiddel indeholdende disse forbindelser, deres anvendelse og fremgangsmåder til deres fremstilling
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
EP1472213B1 (en) 2002-02-05 2010-06-09 Wyeth a Corporation of the State of Delaware Process for the synthesis of n-acyl-2-amino-4-alkoxy-5-nitrobenzoic acids
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
AU2003231231A1 (en) 2002-05-06 2003-11-11 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
EA013248B1 (ru) * 2002-12-20 2010-04-30 Пфайзер Продактс Инк. Производные пиримидина для лечения патологического роста клеток
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
US7235562B2 (en) 2007-06-26
JP2007537238A (ja) 2007-12-20
US20050256111A1 (en) 2005-11-17
TW200612949A (en) 2006-05-01
MXPA06013165A (es) 2007-02-13
CA2564199A1 (en) 2005-11-24
WO2005111016A1 (en) 2005-11-24
EP1758887A1 (en) 2007-03-07
AR049424A1 (es) 2006-08-02

Similar Documents

Publication Publication Date Title
BRPI0510980A (pt) derivados de pirimidina para o tratamento do crescimento anormal de células
BRPI0511132A (pt) derivados de pirimidina e composição farmacêutica compreendendo os mesmos
TNSN06074A1 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
MX2009011090A (es) Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal.
TW200612949A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
UA89123C2 (ru) Производные пиримидина для лечения абнормального роста клеток
EA200971104A1 (ru) Производные бензимидазола
TW200720268A (en) 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors
CO5640039A2 (es) Compuesto de pirazol-amida sustituidos utiles como inhibidores de cinasa
NO20061194L (no) Mitotiske kinesininbibitorer
BR0317435A (pt) Derivados de pirimidina para o tratamento do crescimento celular anormal
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
EA201100874A1 (ru) Соединения для лечения рака
BRPI0511138A (pt) derivados de pirimidina para o tratamento de desenvolvimento celular anormal
TW200720232A (en) Crystalline solid forms of tigecycline and methods of preparing same
BRPI0713381A2 (pt) composto, composição farmacêutica, e, método para o tratamento de uma doença
ATE543803T1 (de) 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren
WO2007076087A3 (en) 3-aryl-substituted quinazolones, and uses thereof
NZ591837A (en) Amino acid derivative
MX2009012079A (es) Compuestos heterociclicos condensados como inhibidores de proteina cinasas.
UA93313C2 (en) Benzimidazole derivatives
WO2006119402A3 (en) C-linked glucoronide of n-(4-hydroxybenzyl) retinone, analogs thereof, and method of using the same to inhibit neoplastic cell growth
CU20060216A7 (es) Derivados de pirimidina para tratar el crecimiento celular anómalo
DOP2005000086A (es) Derivados de pirimidina para tratar el crecimiento celular anomalo
GB0402101D0 (en) Organic compounds

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A E 6 ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE A 8.6 NA RPI 2099 DE 29/03/2011.